# Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants

> **NCT00267150** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 31 (actual)

## Conditions studied

- Pancreas Transplantation
- Kidney Transplantation

## Interventions

- **DRUG:** Enteric-coated mycophenolate sodium (EC-MPS)

## Key facts

- **NCT ID:** NCT00267150
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2011-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00267150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00267150, "Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00267150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*